Zekerie Redzheb

Zekerie is a master’s student in virology, a researcher in antiviral treatment and immunotherapy at Sofia University, and tutors general and molecular biology. He has a vested interest in pandemic viruses and pathogen-host interactions. He is particularly interested in HIV cure research, treatment and management as well as environmental and socicultural influences on the wellbeing of people living with HIV. He holds a joint bachelor’s degree in Biological Sciences and English Literature. Linkedin: www.linkedin.com/in/zekerie-redzheb

Changing treatment

Zekerie Redzheb

Changing HIV treatment

What are logs in viral load results?

HIV lifecycle

Varying dolutegravir distribution across the body may affect the drug’s ability to suppress the HIV reservoir

Dolutegravir-based triple therapy effectively suppresses HIV-2 viral load in small study

Dolutegravir resistance is rare, but some risk factors can up the odds

Gene editing may not be the safest HIV cure strategy, early findings warn

Nearly 13% of participants in an African cohort maintain HIV control off treatment

Increasing and changing pattern of treatment switches among people with HIV

Dolutegravir may increase blood clotting affecting stroke and heart attack risk, early findings warn

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure

HIV in the brain – does it correlate with neurocognitive symptoms?

Man controls HIV for 23 years after a short course of treatment

Defective HIV particles may drive inflammation despite long-term viral suppression

New genetic variant found in those of African ancestry halves HIV viral load

Defective HIV contributes to detectable viral load despite effective treatment

Dolutegravir alone maintains HIV suppression in those treated early

Can testing for drug-gene interactions improve treatment success in people with HIV?